Physician profile
Sandy Menard
NPI 1033717418
$881.50
in general payments reported to CMS, 2019-2025
13 companies · $297 in 2025
The $297 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $417 · 2024: $168 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $301.79 | 2023-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $215.45 | 2023-2025 | Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $53.21 | 2023-2024 | Dupixent |
| Genzyme Corporation | $52.68 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $43.47 | 2024 | Voquezna |
| Amgen INC. | $37.57 | 2023 | Tezspire |
| Grifols USA, LLC | $36.91 | 2025 | Prolastin-C Liquid, Xembify |
| Csl Behring | $29.75 | 2025 | Hizentra |
| Ars Pharmaceuticals Operations, INC. | $27.47 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $24.19 | 2023 | Cuvitru |
| Biocryst US Sales Co., LLC | $23.33 | 2025 | Orladeyo |
| Organon LLC | $20.97 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $14.71 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Menard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.